IKZF5 Knockout Jurkat Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal Jurkat T cell population harboring targeted disruption of the IKZF5 gene. This pooled knockout format provides a heterogeneous loss-of-function model suitable for population-level analyses, avoiding clonal selection artifacts. The cells retain parental Jurkat characteristics while enabling study of IKZF5-dependent processes in T cell biology and leukemia.
The Jurkat cell line is an IL-2-independent, CD4+ human T lymphocyte model originating from acute T cell leukemia. Widely used for T cell receptor signaling and leukemogenesis research, its rapid proliferation and suspension growth make it ideal for high-throughput studies. The malignant background sensitizes the cells to genetic perturbations, providing a context for evaluating tumor suppressor mechanisms.
IKZF5 encodes a zinc finger transcriptional repressor that is essential for lymphocyte development and functions as a tumor suppressor. It operates downstream of NOTCH1 and T cell receptor signaling, and is activated by the IL-7R/JAK1/STAT5 cascade. Through its zinc finger domains, IKZF5 binds DNA and represses transcription of critical target genes, including CDKN1A (p21) and BCL2L1 (BCL-xL), thereby controlling cell cycle progression and apoptosis. The repressive activity is mediated in part by interactions with other Ikaros family members (IKZF1, IKZF3) and the Mi-2/NuRD chromatin remodeling and deacetylase complex, which contains HDAC1 and HDAC2. These interactions place IKZF5 at the center of a network that integrates extracellular growth and survival signals with epigenetic gene silencing, with pathway components such as NOTCH1, HES1, IL7R, JAK1, STAT5, IKZF5, and CDKN1A cooperating to regulate lymphocyte homeostasis. Dysregulation of IKZF5 contributes to acute lymphoblastic leukemia and immunodeficiency.
In Jurkat cells, IKZF5 knockout disrupts a key tumor-suppressive node, derepressing downstream targets and promoting proliferation and survival. This enables dissection of the balance between oncogenic NOTCH1 signaling and IKZF5-mediated repression. The model supports investigation of how IKZF5 loss cooperates with existing leukemic perturbations, and can be employed to screen for agents that restore growth control or target aberrant downstream pathways.
This polyclonal knockout model is a versatile tool for functional genomics, drug target validation, and mechanistic dissection of Notch and IL-7R signaling pathways in T cell leukemia. Researchers can employ Western blotting and RT-qPCR to assess IKZF5 disruption levels and downstream target expression changes. Proliferation and apoptosis assays enable quantification of growth and survival phenotypes, while flow cytometry facilitates analysis of cell surface marker profiles. RNA-sequencing provides transcriptome-wide insights, and ChIP-qPCR permits examination of IKZF5 occupancy at promoters such as CDKN1A. Additionally, drug sensitivity screens can identify small molecules that selectively inhibit IKZF5-deficient cells, offering a platform for targeted therapy development. For further product information, contact Ascent Research.
